|Mr. John F. Thero||Pres, CEO & Director||1.34M||2.79M||1961|
|Mr. Michael W. Kalb||CFO, Sr. VP & Assistant Sec.||672.6k||6.74M||1971|
|Dr. Steven B. Ketchum||Pres of R&D, Sr. VP and Chief Scientific Officer||837.7k||1.55M||1965|
|Mr. Joseph T. Kennedy||Exec. VP, Gen. Counsel & Strategic Initiatives and Sec.||797.7k||12.4M||1968|
|Mr. Aaron D. Berg||Sr. VP & Chief Commercial Officer||673.59k||5.43M||1963|
|Ms. Elisabeth Schwartz||Sr. Director of Investor Relations||N/A||N/A||N/A|
|Mr. Daniel S. Dunham||Sr. VP & Chief Pharmaceutical Compliance Officer||N/A||N/A||N/A|
|Alina Kolomeyer||Director of Communications||N/A||N/A||N/A|
|Mr. Rami Daoud||Sr. VP of Corp. Devel.||N/A||N/A||N/A|
|Ms. Donna Pasek||Sr. VP of HR||N/A||N/A||N/A|
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Amarin Corporation plc’s ISS governance QualityScore as of 1 April 2021 is 8. The pillar scores are Audit: 7; Board: 8; Shareholder rights: 8; Compensation: 7.